Live

CAR-T therapy

3 articles

Tempest's Dual-Targeting CAR-T Shows Promise as Clinical Data Update Looms

GlobeNewswire Inc.

GlobeNewswire Inc.·Apr 29·Na

Tempest's Dual-Targeting CAR-T Shows Promise as Clinical Data Update Looms

Tempest Therapeutics will present updated TPST-2003 CAR-T trial data at ISCT 2026, building on earlier 100% complete response rates in multiple myeloma patients.

TPSTclinical trialmultiple myeloma

Legend Biotech Surges 18% on Bullish Analyst Calls and Sector M&A Momentum

The Motley Fool

The Motley Fool·Apr 20·Eric Volkman

Legend Biotech Surges 18% on Bullish Analyst Calls and Sector M&A Momentum

Legend Biotech surges 18% on bullish analyst upgrades and momentum from Eli Lilly's $7B CAR-T acquisition, with CD19/CD20 therapy driving investor enthusiasm.

LLYLEGNacquisitionanalyst upgrade

Gilead to Acquire Arcellx for $7.8B, Expanding CAR-T Therapy Portfolio

Investing.com

Investing.com·Feb 23·Timothy Fries

Gilead to Acquire Arcellx for $7.8B, Expanding CAR-T Therapy Portfolio

Gilead acquires Arcellx for $7.8B to expand CAR-T therapy portfolio, strengthening oncology pipeline and cell therapy capabilities.

GILDACLXacquisitionFDA approval